Allergy Therapeutics Plc has received a public opening position disclosure/dealing disclosure from Cavendish Securities Plc, an exempt principal trader. The disclosure is made in accordance with Rule 8.5 of the Takeover Code. Cavendish Securities Plc is connected to Allergy Therapeutics Plc, the offeror/offeree in this case. The date of the position held/dealing undertaken is 8/11/2023.
In terms of positions, Cavendish Securities Plc owns and/or controls 155,667 relevant securities of Allergy Therapeutics Plc, which represents 0.00% of the total. There are no cash-settled derivatives or stock-settled derivatives (including options) and agreements to purchase/sell. All interests and short positions have been disclosed.
Regarding dealings, Cavendish Securities Plc has made sales of 123,621 securities of Allergy Therapeutics Plc at a highest price per unit of 1.43 and a lowest price per unit of 1.43. There are no cash-settled derivative transactions, stock-settled derivative transactions, or other dealings.
No indemnity or other dealing arrangements have been disclosed, and there are no agreements, arrangements, or understandings relating to options or derivatives. No supplemental form 8 (open positions) is attached to the disclosure.
The disclosure was made on 9/11/2023, and the contact person for further information is Jennifer O'Donnell at Cavendish Securities Plc.